Investigating the effects of cimetidine on protoporphyrias
Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 submitted 9/2/2020)
This study is looking at how a common stomach medication called cimetidine might help people with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) by reducing their sensitivity to light and other problems caused by a buildup of a substance in their bodies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11086706 on NIH RePORTER |
What this research studies
This research focuses on erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), genetic conditions that cause severe sensitivity to light and other complications. The study aims to evaluate the potential of cimetidine, a medication traditionally used for stomach issues, to inhibit a key enzyme involved in heme biosynthesis, which may help reduce the harmful accumulation of protoporphyrin IX in patients. By exploring this treatment, the research seeks to provide an alternative therapy for patients who currently have limited options for managing their symptoms and preventing serious complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with erythropoietic protoporphyria or X-linked protoporphyria who experience severe light sensitivity and related health issues.
Not a fit: Patients with other forms of porphyria or those who do not have a diagnosis of protoporphyria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new treatment option that alleviates symptoms and reduces the risk of life-threatening complications for patients with protoporphyrias.
How similar studies have performed: Previous case reports have suggested that cimetidine may be beneficial for treating certain types of porphyria, indicating potential for success in this novel application.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Dickey, Amy Kathryn — Massachusetts General Hospital
- Study coordinator: Dickey, Amy Kathryn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.